Slideshow ( 2 images )

ZURICH (Reuters) - Novartis has 25 potential blockbuster treatments in development, the company said ahead of a management event in the United States on Thursday.

“Our pipeline is industry-leading with more than 25 potential blockbusters and this pace of innovation positions Novartis well for the future”, said Novartis Chief Executive Vas Narasimhan in a statement.